Pacer Advisors Inc. Has $7.50 Million Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Pacer Advisors Inc. reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 64.4% during the third quarter, Holdings Channel reports. The institutional investor owned 92,113 shares of the medical equipment provider’s stock after selling 166,682 shares during the period. Pacer Advisors Inc.’s holdings in Hologic were worth $7,504,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in HOLX. Cetera Investment Advisers raised its position in shares of Hologic by 188.9% during the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock worth $1,595,000 after purchasing an additional 13,380 shares during the period. Andra AP fonden raised its holdings in Hologic by 224.5% during the second quarter. Andra AP fonden now owns 95,400 shares of the medical equipment provider’s stock worth $7,083,000 after buying an additional 66,000 shares during the last quarter. Swedbank AB raised its holdings in Hologic by 5.2% during the second quarter. Swedbank AB now owns 1,630,440 shares of the medical equipment provider’s stock worth $121,060,000 after buying an additional 80,575 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after buying an additional 582 shares in the last quarter. Finally, Comerica Bank grew its holdings in shares of Hologic by 40.9% during the first quarter. Comerica Bank now owns 110,053 shares of the medical equipment provider’s stock valued at $8,580,000 after buying an additional 31,967 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Mizuho dropped their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Evercore ISI raised their target price on Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Citigroup cut Hologic from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $95.00 to $85.00 in a research note on Tuesday, October 1st. Finally, Royal Bank of Canada upped their target price on shares of Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and an average price target of $89.91.

Hologic Stock Performance

NASDAQ HOLX opened at $78.97 on Friday. The company has a market capitalization of $18.34 billion, a PE ratio of 23.71, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The company has a 50-day simple moving average of $80.44 and a 200 day simple moving average of $78.34.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the firm posted $0.89 EPS. Hologic’s revenue was up 4.5% on a year-over-year basis. On average, research analysts predict that Hologic, Inc. will post 4.27 EPS for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.